購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
KS (inducible) Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
KS (inducible) Mouse
製品名
KS (inducible) Mouse
製品ID
C001514
系統名
C57BL/6JCya-Krastm1(LSL-G12D)Sftpcem2(IERS-MerCreMer)/Cya
背景情報
C57BL/6JCya
Note
This product is shipped by default as uninduced mice. The recommended induction protocol is shown at the end of this manual. If you need induced mice, please contact us in advance.
状況
このマウス系統を論文で使用する場合は、「KS (inducible) Mouse(カタログ番号C001514)はサイアジェンから購入しました。」と引用してください。
Disease Animal Models
Spontaneous Tumor
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Disease Animal Models
Spontaneous Tumor
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
ras, p21B, K-Ras, K-ras, Kras2, Ki-ras, Kras-2, K-Ras 2, c-K-ras, c-Ki-ras
NCBI ID
染色体
Chr 6
MGI ID
さらに
系統詳細
KRAS is an oncogene that encodes the K-Ras protein, a key component of the RAS/MAPK signaling pathway. The K-Ras protein plays an important regulatory role in various cellular processes, including cell growth, proliferation, maturation, and differentiation. KRAS gene mutations are a common cause of cancer, with approximately 30% of cancer patients harboring KRAS mutations. These mutations are predominantly single-nucleotide missense mutations, with over 80% occurring at the 12th amino acid residue (G12), particularly the KRAS G12D mutation, which is very common in lung and pancreatic cancers. The G12D mutation enhances the activity of the K-Ras protein, leading to uncontrolled cell growth and division, thereby promoting tumor formation. The K-Ras protein is highly conserved between mice and humans, with only differences at the 132nd and 187th amino acid residues[1-2].
The SFTPC gene encodes surfactant protein C (SP-C), one of the four major proteins that make up surfactant. Surfactant is a mixture of lipids and proteins that coats the surface of lung tissue, reducing respiratory resistance. It is produced and secreted by alveolar cells, and its main function is to maintain the stability of lung tissue by reducing the surface tension of lung fluid. In addition, SP-C protein is involved in lung development and function, including alveolar formation, airway remodeling, and immune defense. The SFTPC gene is expressed primarily in the lung, with the highest expression in the lower lobes, right lung, upper lobes, left upper lobes, and visceral pleura. It is also expressed at lower levels in other tissues. Type II alveolar cells are the main producers and secretors of surfactants, and the SFTPC gene is highly expressed in these cells, making it a specific marker of this cell type.
The KS (inducible) mouse is an induced lung cancer model that is constructed by crossing LSL-K-ras G12D mice (Catalog number: C001064), a conditional over-expressing K-Ras G12D mutant gene mouse strain, and Sftpc-MerCreMer mice (Catalog number: C001501), a type II alveolar cell-specific Cre recombinase expressing mouse strain, and then inducing with tamoxifen. Tamoxifen can trigger sequence recombination between loxP sites mediated by Cre recombinase in the type II alveolar cells of the offspring mice, resulting in the specific deletion of the Loxp-Stop-Loxp (LSL) gene silencing element in the type II alveolar cells, thereby enabling the K-Ras G12D mutant gene to be selectively expressed in the lung tissue. Internal data indicates that the model may exhibit slight expression leakage in the absence of tamoxifen induction, leading to the occurrence of a small number of pulmonary adenomas.
参考文献
Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer. 2018 Dec;18(12):767-777.
Filiberti A, Ventafridda V, Costa A. What is the best treatment for early breast cancer? A psychosocial answer. Ann Oncol. 1995 May;6(5):417-9.
系統作製戦略
Generated by crossing LSL-K-ras G12D mice with Sftpc-MerCreMer mice.
適用分野
KS (inducible) mice can be used to study the mechanisms of the occurrence and metastasis of non-small cell lung cancer (NSCLC), as well as the screening, development, and evaluation of therapeutic drugs.
検証 Data
1. Survival and growth curves
KS mice at 4 weeks of age were induced to develop lung cancer by intraperitoneal injection of 75 mg/kg tamoxifen for 4 consecutive days. The survival rate and weight changes of the mice were monitored. (Note: All mice in subsequent experiments in this manual were induced with tamoxifen according to this protocol.) The results showed that the weight of KS mice significantly decreased after tamoxifen induction. The mice started to die after 9 weeks of induction. The mortality rate of KS mice reached 100% at 13 weeks after induction.

Figure 1. Survival and weight change of KS mice (n=10).
2. CT scan of the lungs
Results showed that 6 weeks after tamoxifen induction at 4 weeks of age, KS mice developed diffuse, multiple nodular and patchy high-density shadows in both lungs. This indicates extensive pulmonary parenchymal space-occupying or neoplastic lesions (represented by the lighter shaded areas in the figure).

Figure 2. Lung CT scans of KS and wild-type mice at 6 weeks after tamoxifen induction.
3. Morphology of the lungs (3 weeks after induction)
Tamoxifen induction was carried out in KS mice at 4 weeks of age, and the mice were dissected 3 weeks after completion of induction. The results showed that the lungs of KS mice in the tamoxifen-induced group showed significant hyperplasia and enlargement at 3 weeks after completion of induction compared with those of KS mice in the non-induced group.

Figure 3. Lung morphology of female and male KS mice 3 weeks after tamoxifen induction.
4. Morphology of the lungs and spleen (6, 9 and 12 weeks after induction)
The results showed that KS mice treated with tamoxifen at 4 weeks of age developed tumor tissue growth and invasion in the lungs 6 weeks after induction, with the lungs showing a dense and enlarged structure. At 12 weeks after induction, the spleens of KS mice showed abnormal hyperplasia.

Figure 4. Morphology of the lungs and spleens of female KS mice and wild-type control mice at 6, 9, and 12 weeks after tamoxifen induction.
5. Hematoxylin and Eosin (H&E) staining
(1)Lung lesions
KS mice induced with tamoxifen at 4 weeks of age exhibited significant pulmonary infiltration compared to controls. Notably, distinct lung lesions emerged after 6 weeks of induction and further aggravated by 12 weeks.

Figure 5. The H&E staining results of lung tissue from female KS mice treated with tamoxifen or corn oil at 6 and 12 weeks.
(2)Typical types of lung lesions
Tamoxifen induction was performed in KS mice at 4 weeks of age. Compared to the control group, the tamoxifen-induced KS mice showed pulmonary consolidation, reduced alveolar air content, and increased lung density after 6 weeks of induction. At 9 weeks, they exhibited pulmonary adenomas originating from type II alveolar epithelial cells. By 12 weeks, pulmonary adenocarcinomas derived from bronchial epithelial cells were observed, characterized by granular and refractive features (mucus shown by red arrow).

Figure 6. H&E staining results of lung tissue from KS mice treated with tamoxifen and corn oil at 6, 9, and 12 weeks.
(3)H&E staining of other tissues
The results showed that compared with the control group, the kidneys, liver, and pancreas of KS mice treated with tamoxifen for 12 weeks were normal, while the spleen showed abnormal hyperplasia of white pulp.

Figure 7. The H&E staining results of kidneys, liver, spleen, and pancreas from female KS mice treated with tamoxifen or corn oil at 12 weeks.
関連リソース
お問い合わせ
ご不明な点やご質問などございましたら、お気軽にお問い合わせください。担当スタッフがサポートさせていただきます。下記のフォームにご記入いただければ、1〜2営業日以内に折り返しご連絡いたします。
Related Product
All Related ProductsResources
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
